Thyroid Dysfunction and Immunotherapy Response
Author Information
Author(s): I. Reid, I. Sharpe, J. McDevitt, W. Maxwell, R. Emmons, W.A. Tanner, J.R.T. Monson
Primary Institution: Department of Surgery, Meath Hospital, Dublin, Ireland
Hypothesis
Can thyroid dysfunction predict response to immunotherapy with interleukin-2 and interferon-2a?
Conclusion
Patients who developed thyroid dysfunction during treatment had longer survival compared to those with normal thyroid function.
Supporting Evidence
- Six out of thirteen patients developed thyroid dysfunction during treatment.
- Patients with thyroid dysfunction had a median survival of 13.5 months.
- All patients with normal thyroid function died within 1.5 to 7 months after starting therapy.
- Statistical analysis showed a significant difference in survival between groups with and without thyroid dysfunction.
Takeaway
This study looked at how thyroid problems might help doctors understand if cancer treatment is working. It found that patients with thyroid issues during treatment lived longer.
Methodology
Patients were treated with interleukin-2 and interferon-2a in a non-randomized study, with thyroid function monitored throughout treatment.
Potential Biases
Potential bias due to non-randomized study design.
Limitations
The small sample size limits the ability to draw definitive conclusions.
Participant Demographics
Median age of participants was 59 years, with a range from 32 to 70 years; all had normal thyroid function at the start.
Statistical Information
P-Value
0.049
Statistical Significance
p=0.049
Want to read the original?
Access the complete publication on the publisher's website